Mobile website
Prompt Report
Changes in regulatory T cells of lung cancer patients before and after GM-CSFmodified tumor cell vaccine treatment and their clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To observe the alteration in proportion of CD4+CD25+ regulatory T cells (Tregs) in the peripheral blood of lung cancer patients treated with GMCSF modified tumor cell vaccine (GVAX) and its relationship to clinical characteristics and survival rate of lung cancer patients. Methods: Eightyfive lung cancer patients treated with GVAX in Affiliated Tumor Hospital of Tianjin Medical University were enrolled in the present study, including 28 squamous carcinoma, 47 adenocarcinoma, 10 small cell lung cancers, among which 23 in early stage (Ⅰ~ⅢA), 62 in advanced stage (ⅢB~Ⅳ). The proportion of Tregs in the peripheral blood before and after GVAX treatment was detected by flow cytometry, and the correlation between the alteration of Treg proportional and clinicopathological characteristics and overall survival of lung cancer patients were analyzed.Results: Oneyear, 3year survival rates of 85 patients with lung cancer treated with GVAX were 69.3% and 48.2%, respectively. The proportion of Treg in peripheral blood significantly decreased after GVAX treatment (\[4.86±2.52\]% vs \[5.52±2.68\]%, P<0.05). The proportion of Tregs significantly decreased in the patients with normal LDH level (\[4.50±2.23\]% vs \[5.59±2.76\]%, P<0.05) while increased in those with high LDH level (\[6.00±3.06\]% vs \[5.30±2.47\]%, P<0.05) after GVAX treatment. The proportion of Tregs decreased more dramatically in the patients treated with GVAX more than 1 course than in those patients with only 1 course (\[-2.11±1.620\]% vs \[-0.39±2.39\]%, P<0.05). The alteration of Treg proportion after GVAX treatment was tightly related to the prognosis of the patients. Patients with a decrease of Tregs showed longer overall survival (OS) than those displaying an increase of Treg after GVAX treatment (21 months vs 10 months, P<0.05), especially patients in advanced stage (18 months vs 8 months, P<0.05). Conclusion: The alteration of Treg proportion in peripheral blood could be a potential immunological indicator to evaluate the efficacy and prognosis of lung cancer patients who received GVAX treatment. The declining pattern of Treg after GVAX treatment implies a better prognosis of patients.
Keywords:
Project Supported:
Project supported by the National Key Science and Technology Research Program (No. 2005BA740C), and the Special Foundation for Science and Technology Innovation of Tianjin Province（No. 06FZZDSF01500）
Clc Number:
